# Divamics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/divamics

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.divamicsbio.com
- Latest round: Series A (May 6, 2025)
- Investors on record: 2

## About

Established in 2021 and based in Suzhou, China, Divamics operates as a biopharmaceutical company that focuses on providing AI pharmaceutical services. Zheng Zheng, the company's founder and CEO, has a PhD in Chemistry from the University of Florida. In May 2025, the company closed series A funding from new investors YuanBio Venture. In August 2025, Divamics closed a Strategic Investment from new investor Suzhou Angel Investment Guidance Fund. The company focuses on new drug research and development. The main products are computational chemistry services and new drug research and development pipeline projects based on artificial intelligence drug research and development platforms. Computational chemistry services include target drugability analysis, high-flexibility target modeling, and macromolecular and small molecule drug structure screening. The new drug research and development pipeline includes IMC001, IMC002, IMC008, etc. Among them, IMC001 is indicated for EpCAM-positive advanced gastric cancer and esophagogastric junction adenocarcinoma. The company generates revenue by providing computational chemistry services and new drug research and development services.

## Funding rounds

- Series A, May 6, 2025 — YuanBio Venture
- Angel, May 1, 2022 — Shileng Investment

## Investors

- Shileng Investment (https://capitalatlas.ai/funds/shileng-investment) — Angel
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A